Fig 1.
Acute otitis media–Faces scale.
Faces scale as used in the study and reproduced with permission of the authors [9].
Fig 2.
Symptom questions asked of carers of children enrolled in the WATCH trial, inclusive of the AOM SOS scale items (collected at enrolment and days 3, 7 and 14).
*blue shaded items correspond to the Acute Otitis Media-Severity of Symptoms scale (AOM-SOS version 3.0). NB: in AOM-SOS version 4.0, items 11 and 12 above are omitted.
Fig 3.
Distribution of the AOM-FS and AOM-SOS (version 4) symptom scores by days since enrolment into trial.
The distribution of scores within each time point is plotted using a combination of a violin (represented by a shaded plot), a boxplot (represented by a box), and data points (represented by dots). The width of a violin plot represents the number of results within that score. The boxes indicate the 25th (lower horizontal line), median (middle horizontal line), and 75th (upper horizontal lines) percentiles of the distribution. Dot plots are jittered to increase visibility. The red line indicates the trend in median values over time. Lower values indicate lesser symptom severity. Day 7 and 14 boxplot lines for 25th percentile and median overlap due to more children having lower scores.
Fig 4.
Responsiveness of AOM-FS and AOM-SOS (version 4) symptom scales to clinical changes by days after enrolment to trial.
The distribution of scores within each time point is plotted using a combination of a violin (represented by a shaded plot), a boxplot (represented by a box), and data points (represented by dots). The width of a violin plot represents the number of results within that score. The boxes indicate the 25th (lower horizontal line), median (middle horizontal line), and 75th (upper horizontal lines) percentiles of the distribution. Dot plots are jittered to increase visibility. The red line indicates the trend in median values over time. Lower values indicate lesser symptom severity. Day 7 and 14 boxplot lines for 25th percentile and median overlap due to more children having lower scores.
Table 1.
Prevalence of symptoms associated with AOM in children enrolled at baseline (day 0).
Table 2.
Severity of symptoms at enrolment into WATCH trial (baseline) compared with primary endpoint time (day 7), stratified by AOM resolution at Day 7.